Literature DB >> 23641139

Improving anticoagulation management in patients with atrial fibrillation.

John R Fanikos, Julie K Atay, Jean M Connors.   

Abstract

Three agents have recently been approved to reduce the risk of stroke and embolism, and one agent is in phase 3 trials. These drugs cause less serious bleeding and are simpler to manage, compared with warfarin, but they are not without their risks.

Entities:  

Year:  2013        PMID： 23641139      PMCID： PMC3638402     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  25 in total

Review 1.  New antithrombotics for atrial fibrillation.

Authors:  Luke R E Bereznicki; Gregory M Peterson
Journal:  Cardiovasc Ther       Date:  2010-07-14       Impact factor: 3.023

Review 2.  Recombinant activated factor VII use in the emergency department.

Authors:  P E Fishman; B C Drumheller; M E Dubon; T L Slesinger
Journal:  Emerg Med J       Date:  2008-10       Impact factor: 2.740

Review 3.  Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

Authors:  Joanne van Ryn; Joachim Stangier; Sebastian Haertter; Karl-Heinz Liesenfeld; Wolfgang Wienen; Martin Feuring; Andreas Clemens
Journal:  Thromb Haemost       Date:  2010-03-29       Impact factor: 5.249

4.  Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).

Authors:  Christian T Ruff; Robert P Giugliano; Elliott M Antman; Sharon E Crugnale; Tomas Bocanegra; Michele Mercuri; James Hanyok; Indravadan Patel; Minggao Shi; Dan Salazar; Carolyn H McCabe; Eugene Braunwald
Journal:  Am Heart J       Date:  2010-10       Impact factor: 4.749

5.  Apixaban in patients with atrial fibrillation.

Authors:  Stuart J Connolly; John Eikelboom; Campbell Joyner; Hans-Christoph Diener; Robert Hart; Sergey Golitsyn; Greg Flaker; Alvaro Avezum; Stefan H Hohnloser; Rafael Diaz; Mario Talajic; Jun Zhu; Prem Pais; Andrzej Budaj; Alexander Parkhomenko; Petr Jansky; Patrick Commerford; Ru San Tan; Kui-Hian Sim; Basil S Lewis; Walter Van Mieghem; Gregory Y H Lip; Jae Hyung Kim; Fernando Lanas-Zanetti; Antonio Gonzalez-Hermosillo; Antonio L Dans; Muhammad Munawar; Martin O'Donnell; John Lawrence; Gayle Lewis; Rizwan Afzal; Salim Yusuf
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

6.  Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.

Authors:  Koichiro Ogata; Jeanne Mendell-Harary; Masaya Tachibana; Hiroshi Masumoto; Toshihiro Oguma; Masazumi Kojima; Satoshi Kunitada
Journal:  J Clin Pharmacol       Date:  2010-01-15       Impact factor: 3.126

7.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

8.  Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Daniel E Singer; Gregory W Albers; James E Dalen; Margaret C Fang; Alan S Go; Jonathan L Halperin; Gregory Y H Lip; Warren J Manning
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

Review 9.  Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents.

Authors:  M A Crowther; T E Warkentin
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

Review 10.  Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management.

Authors:  M M Levi; E Eerenberg; E Löwenberg; P W Kamphuisen
Journal:  Neth J Med       Date:  2010-02       Impact factor: 1.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.